Antimicrobial therapy quickly eradicates susceptible bacilli, but the fight against drug-resistant disease must be waged entirely by host defenses. Knowledge of the two main types of immune response against tuberculosis and of how to manipulate those mechanisms—leading to precisely designed recombinant BCG vaccines—is essential to mounting an effective attack on the current epidemic.